News & Media
Valeo Pharma Initiates Restructuring Proceedings Under the CCAA to Implement a Review of its Strategic Alternatives
MONTREAL, QUEBEC, October 1, 2024,— Valeo Pharma Inc. (TSX: VPH, FSE: VP2), a Canadian pharmaceutical company, announced today that the Québec Superior Court...
Latest News
VALEO PHARMA REPORTS THIRD QUARTER 2024 REVENUES
Q3-24 revenues of $12.6 million, down 11% from Q3-23, excluding XIIDRA, growth...
VALEO PHARMA TO HOST THIRD QUARTER 2024 RESULTS CONFERENCE CALL / WEBCAST
MONTREAL, QUEBEC , September 9, 2024 – Valeo Pharma Inc. (TSX:VPH, OTCQB:...
VALEO PHARMA AMENDS CREDIT FACILITY WITH SAGARD HEALTHCARE ROYALTY PARTNERS, LP
MONTREAL, QUEBEC, September 3, 2024 – Valeo Pharma Inc. (TSX: VPH, FSE: VP2)...
VALEO PHARMA ANNOUNCES VOLUNTARY DELISTING FROM OTCQB VENTURE MARKET
MONTREAL, QUEBEC, August 29, 2024 – Valeo Pharma Inc. (TSX: VPH, OTCQB: VPHIF,...
VALEO PHARMA ANNOUNCES LEADERSHIP CHANGES
MONTREAL, QUEBEC, August 6, 2024 – Valeo Pharma Inc. (TSX: VPH, OTCQB: VPHIF,...
VALEO PHARMA ANNOUNCES SENIOR EXECUTIVE APPOINTMENT AND BOARD OF DIRECTORS CHANGE
MONTREAL, QUEBEC, June 18, 2024 – Valeo Pharma Inc. (TSX: VPH, OTCQB: VPHIF,...
VALEO PHARMA REPORTS RECORD SECOND QUARTER 2024 REVENUES
Record Q2-24 revenues of $14.1 million, up 4% over Q2-23 outpacing revenue...
VALEO PHARMA ANNOUNCES RESTRUCTURING OF COMMERCIAL FIELD OPERATIONS TO SUPPORT PATH TO PROFITABILITY
Changes to respiratory business unit to generate more than $5 million in...
VALEO PHARMA TO HOST SECOND QUARTER 2024 RESULTS CONFERENCE CALL / WEBCAST
MONTREAL, QUEBEC , June 4, 2024 – Valeo Pharma Inc. (TSX:VPH, OTCQB: VPHIF,...
VALEO PHARMA ANNOUNCES RESULTS OF ANNUAL MEETING OF SHAREHOLDERS
MONTREAL, QUEBEC , April 25, 2024 – Valeo Pharma Inc. (TSX:VPH, OTCQB: VPHIF,...
VALEO PHARMA TO PRESENT AT THE 2024 BLOOM BURTON & CO HEALTHCARE INVESTOR CONFERENCE
MONTREAL, QUEBEC, April 9, 2024 – Valeo Pharma Inc. (TSX: VPH, OTCQB: VPHIF,...
VALEO PHARMA ANNOUNCES APPOINTMENT OF MR. AL MOGHADDAM TO BOARD OF DIRECTORS
MONTREAL, QUEBEC, March 22, 2024 – Valeo Pharma Inc. (TSX: VPH, OTCQB: VPHIF,...
VALEO PHARMA REPORTS FIRST QUARTER 2024 RESULTS
Q1-24 revenues of $13.5 million, up 3% over Q1-23 Q1-24 adjusted EBITDA loss...
VALEO PHARMA TO HOST FIRST QUARTER 2024 RESULTS CONFERENCE CALL / WEBCAST
MONTREAL, QUEBEC , March 7, 2024 – Valeo Pharma Inc. (TSX:VPH, OTCQB: VPHIF,...
VALEO PHARMA ANNOUNCES BOARD OF DIRECTORS CHANGES
MONTREAL, QUEBEC, February 13, 2024 – Valeo Pharma Inc. (TSX: VPH, OTCQB:...
VALEO PHARMA AMENDS AGREEMENT WITH NOVARTIS PHARMACEUTICALS CANADA FOR XIIDRA® IN CANADA AND CREDIT FACILITY WITH SAGARD HEALTHCARE ROYALTY PARTNERS, LP
Original commercialization and supply agreement amended following global...
VALEO PHARMA REPORTS RECORD ANNUAL REVENUES FOR FISCAL YEAR 2023
Record revenues of $54 million for fiscal 2023, up 94% over 2022 Revenues of...
VALEO PHARMA TO HOST FOURTH QUARTER AND YEAR-END 2023 RESULTS CONFERENCE CALL / WEBCAST
MONTREAL, QUEBEC , January 22, 2024 – Valeo Pharma Inc. (TSX:VPH, OTCQB:...
VALEO PHARMA ANNOUNCES ORGANIZATIONAL CHANGES AND COST REDUCTION INITIATIVES
Costs reduction initiatives and organizational realignment expected to...
VALEO PHARMA ANNOUNCES APPOINTMENT OF MR. RICHARD LAJOIE TO BOARD OF DIRECTORS
MONTREAL, QUEBEC, November 7, 2023 – Valeo Pharma Inc. (TSX: VPH, OTCQB:...
VALEO PHARMA MAKES THE LIST OF THE GLOBE AND MAIL’S FIFTH-ANNUAL RANKING OF CANADA’S TOP GROWING COMPANIES
MONTREAL, QUEBEC , October 4, 2023 – Valeo Pharma Inc. (TSX:VPH, OTCQB: VPHIF,...
VALEO PHARMA ENTERS INTO $5 MILLION CREDIT FACILITY AGREEMENT WITH ACCORD FINANCIAL INC.
MONTREAL, QUEBEC , September 27, 2023 – Valeo Pharma Inc. (TSX:VPH, OTCQB:...
VALEO PHARMA REPORTS RECORD THIRD QUARTER 2023 REVENUES
Seventh consecutive quarter of revenue growth at $14.1 million in Q3-23, up...
VALEO PHARMA TO HOST THIRD QUARTER 2023 RESULTS CONFERENCE CALL / WEBCAST
MONTREAL, QUEBEC , September 7, 2023 – Valeo Pharma Inc. (TSX:VPH, OTCQB:...
VALEO PHARMA CLOSES $4.5 MILLION FINANCING
$3.92 million raised from non-brokered private placement offering, and $0.58...
VALEO PHARMA PROVIDES UPDATE ON OPHTHALMOLOGY BUSINESS UNIT
Novartis agrees to sell global rights to XIIDRA® and several other...
VALEO PHARMA ANNOUNCES NEW BOARD APPOINTMENTS
MONTREAL, QUEBEC, June 22, 2023 – Valeo Pharma Inc. (TSX: VPH, OTCQB: VPHIF,...
VALEO PHARMA REPORTS RECORD SECOND QUARTER REVENUES
Sixth consecutive quarter of revenue growth at $13.6 million in Q2-23, up 184%...
VALEO PHARMA TO HOST SECOND QUARTER 2023 RESULTS CONFERENCE CALL / WEBCAST
MONTREAL, QUEBEC , June 7, 2023 – Valeo Pharma Inc. (TSX:VPH, OTCQB: VPHIF,...
VALEO PHARMA PROVIDING GUIDANCE OF RECORD REVENUES FOR THE SECOND QUARTER 2023
Q2-23 revenues to exceed $13.5 million Q2-23 adjusted EBITDA loss to decrease...
VALEO PHARMA ANNOUNCES RESULTS OF ANNUAL MEETING OF SHAREHOLDERS AND COMMITTEE APPOINTMENTS
MONTREAL, QUEBEC , April 28, 2023 – Valeo Pharma Inc. (TSX:VPH, OTCQB: VPHIF,...
VALEO PHARMA TO PRESENT AT THE 2023 BLOOM BURTON & CO HEALTHCARE INVESTOR CONFERENCE
MONTREAL, QUEBEC , April 19, 2023 – Valeo Pharma Inc. (TSX:VPH, OTCQB: VPHIF,...
VALEO PHARMA REPORTS RECORD QUARTERLY REVENUES FOR THE FIRST QUARTER 2023
• Fifth consecutive quarter of revenue growth at $13.2 million in Q1-23, up...
VALEO PHARMA TO HOST FIRST QUARTER 2023 RESULTS CONFERENCE CALL / WEBCAST
MONTREAL, QUEBEC , March 9, 2023 – Valeo Pharma Inc. (TSX:VPH, OTCQB: VPHIF,...
VALEO PHARMA OBTAINS PUBLIC REIMBURSEMENT FOR ONSTRYV® IN QUEBEC
Quebec public reimbursement coverage to facilitate and expand medication...
VALEO PHARMA REPORTS RECORD QUARTERLY AND ANNUAL REVENUES FOR THE FOURTH QUARTER AND THE FISCAL YEAR 2022
Record quarterly revenues of $12.7 million in Q4-22, up 274% over Q4-21 Record...
VALEO PHARMA ANNOUNCES FILING OF A NEW DRUG SUBMISSION-COVID 19 WITH HEALTH CANADA FOR SABIZABULIN FOR THE TREATMENT OF HOSPITALIZED COVID-19 PATIENTS
In the final analysis of the Phase 3 cinical study conducted by Veru Inc.,...
VALEO PHARMA TO HOST FOURTH QUARTER AND YEAR-END 2022 RESULTS CONFERENCE CALL / WEBCAST
MONTREAL, QUEBEC , January 25, 2023 – Valeo Pharma Inc. (TSX:VPH, OTCQB:...
Past Press Releases
hidden
2022
2021
2020